Sangmin Lee
Cornell University
63 Papers
159 Citations
Sangmin Lee is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 12, co-authored 50 publications. Previous affiliations of Sangmin Lee include University of Miami & University of Tennessee Health Science Center.
Chat about Author
Papers
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H. Wei,Stephen A. Strickland,Jing Zhou Hou,Walter Fiedler,Tara L. Lin,Roland B. Walter,Roland B. Walter,Anoop K Enjeti,Anoop K Enjeti,Ing Soo Tiong,Michael R. Savona,Sangmin Lee,Brenda Chyla,Relja Popovic,Ahmed Salem,Suresh Agarwal,Tu Xu,Kaffa Fakouhi,Rod A. Humerickhouse,Wan Jen Hong,John Hayslip,Gail J. Roboz +21 more
TL;DR: Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in older adults with AML ineligible for intensive chemotherapy, and high remission rate and low early mortality combined with rapid and Durable remission make venetoclAX and LDAC an attractive and novel treatment for older adults not suitable forintensive chemotherapy.
Somatic mutations precede acute myeloid leukemia years before diagnosis.
Pinkal Desai,Nuria Mencia-Trinchant,Oleksandr Savenkov,Michael S. Simon,Gloria Cheang,Sangmin Lee,Michael B. Samuel,Ellen K. Ritchie,Monica L. Guzman,Karla V. Ballman,Gail J. Roboz,Duane C. Hassane +11 more
TL;DR: The presence of detectable mutations years before diagnosis suggests that there is a period of latency that precedes AML during which early detection, monitoring and interventional studies should be considered.
Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis
TL;DR: Recent studies indicate that antibodies to non-myelin antigens such as neurofilaments, neurofascin, RNA binding proteins and potassium channels may contribute to the pathogenesis of MS.
43
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.
Naveen Pemmaraju,Hagop M. Kantarjian,Kendra Sweet,Eunice S. Wang,Jayastu Senapati,Nathaniel R. Wilson,Marina Konopleva,Arthur E. Frankel,Vikas Gupta,Ruben A. Mesa,M. Ulrickson,Edward J. Gorak,Sumeet Bhatia,Tulin Budak-Alpdogan,James R. Mason,María Teresa García-Romero,Norma Lopez-Santiago,Gabriela Cesarman-Maus,Pankit Vachhani,Sangmin Lee,Vijaya Raj Bhatt,William Blum,Roland B. Walter,Dale L. Bixby,Ivana Gojo,Madeleine Duvic,Raajit K. Rampal,Marcos de Lima,James M. Foran,Amir T. Fathi,Aric C. Hall,Meagan A. Jacoby,Jeffrey E. Lancet,Gabriel N. Mannis,Anthony S. Stein,Alice S. Mims,David A. Rizzieri,Rebecca L. Olin,Alexander E. Perl,Gary J. Schiller,Paul J. Shami,Richard Stone,Stephen A. Strickland,Matthew J. Wieduwilt,Naval Daver,Farhad Ravandi,Sumithira Vasu,Monica L. Guzman,Gail J. Roboz,Joseph D. Khoury,Muzaffar H. Qazilbash,Phyu P. Aung,Branko Cuglievan,Yazan F. Madanat,Mohamed A. Kharfan-Dabaja,Anna B. Pawlowska,Justin Taylor,Martin S. Tallman,Prajwal Dhakal,Andrew N. Lane +59 more
TL;DR: The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDC ages 2 and older as mentioned in this paper .
29
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
Justin M. Watts,Maria R. Baer,Jay Yang,Thomas Prebet,Sangmin Lee,Gary J. Schiller,Shira Dinner,Arnaud Pigneux,Pau Montesinos,Eunice S. Wang,Karen Seiter,Andrew H. Wei,Stéphane de Botton,Montserrat Arnan Sangerman,William B. Donnellan,Brian A. Jonas,Paul Brent Ferrell,Kim Hien T. Dao,Patrick Kelly,Jennifer Sweeney,Sanjeev Forsyth,Sylvie Guichard,Julie Brevard,Patrick Henrick,Hesham Mohamed,Jorge E. Cortes +25 more
TL;DR: This year's finalists were Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, and Sylvie Guichard.
26